Crossmark

Analysis of antihypertensive treatment using real-world Japanese data—the retrospective study of antihypertensives for lowering blood pressure (REAL) study

Crossref DOI link: https://doi.org/10.1038/s41440-019-0238-2

Published Online: 2019-03-06

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ohishi, Mitsuru

Yoshida, Takuo

Oh, Akinori

Hiroi, Shinzo

Takeshima, Tomomi

Otsuka, Yujiro

Iwasaki, Kosuke

Shimasaki, Yukio
License Information

Text and Data Mining valid from 2019-03-06

Version of Record valid from 2019-03-06
More Information

Article History

Received: 10 August 2018

Revised: 12 November 2018

Accepted: 14 November 2018

First Online: 6 March 2019

Compliance with ethical standards

:

: Employment: TY, AO, and YS (Takeda Pharmaceutical Company), SH (formerly employed by Takeda Pharmaceutical Company), TT, YO, and KI (Milliman Inc., which received consultancy fees from Takeda Pharmaceutical Company); Honoraria: MO (MSD, Astellas, Dai-ichi Sankyo Company, Sumitomo Dainippon Pharma, Takeda Pharmaceutical Company, Novartis Pharma, Pfizer, and Boehringer Ingelheim); Fees for promotional materials: MO (Kyowa Kikaku); Research funding: MO (Dai-ichi Sankyo); Scholarship or donation: MO (MSD, Astellas, Kyowa Hakko Kirin, Dai-ichi Sankyo Company, Takeda Pharmaceutical Company, and Boehringer Ingelheim).

Document is current

Any future updates will be listed below